Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society

(2020) Alexander R. Lyon et al.   EUROPEAN JOURNAL OF HEART FAILURE

Recurrent heart failure hospitalizations are associated with increased cardiovascular mortality in patients with heart failure in Clinical Practice Research Datalink

(2020) Raquel Lahoz et al.   ESC Heart Failure

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases

(2019) Helen Strongman et al.   LANCET

Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events

(2018) Rhian M. Touyz et al.   Journal of the American Society of Hypertension

Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor–Associated Hypertension and Vascular Disease

(2017) Arvind K. Pandey et al.   HYPERTENSION

Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients

(2017) Matthias Totzeck et al.   Journal of the American Heart Association

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

Cancer therapy and cardiovascular risk: focus on bevacizumab

(2015) Panagiota Economopoulou et al.   Cancer Management and Research

Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies

(2011) Herbert I. Hurwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Anticancer therapy induced cardiotoxicity: review of the literature

(2010) Sandra Geiger et al.   ANTI-CANCER DRUGS

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Hemostatic complications of angiogenesis inhibitors in cancer patients

(2008) Francesca Elice et al.   AMERICAN JOURNAL OF HEMATOLOGY

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

(2008) Abby B. Siegel et al.   JOURNAL OF CLINICAL ONCOLOGY